PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021
Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com Date
View HTML
Toggle Summary ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer
ERYTECH Announces Results from TRYbeCA-1 Phase 3 Trial of Eryaspase in Patients with Second-line Advanced Pancreatic Cancer Management to host Conference Call on Monday, October 25, at 8:30am EDT/ 2:30pm CEST          T he trial did not meet its primary endpoint of overall survival The prespecified
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – September 30, 2021.
               Monthly information related to total number of voting rights and shares composing the share capital – September 3 0 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Toggle Summary ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces M aximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose - l imiting t oxicity (DLT) reported in first two dose cohorts, leading to de c laration of the m aximum t olerated d ose (MTD) at 100 U/kg Encouraging
View HTML
Toggle Summary ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech
ERYTECH to Participate in the HealthTech Innovation Days (HTID) by France Biotech Cambridge, MA (U.S.) and Lyon (France), September 28 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Announces the Availability of its Half-Year Financial Report 2021
ERYTECH Announces the A vailability of its H alf- Y ear F inancial R eport 202 1 Lyon (France) a nd Cambridge, MA (U.S.), Septembre 2 2 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 20 2 1 Conference call and webcast on Tuesday, September 21, 2021 at 8:30am EDT / 2:30pm CET          TRYbeCA-1 Phase 3 trial of eryaspase in second-line metastatic pancreatic cancer fully enrolled since January
View HTML
Toggle Summary ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update
Lyon (France) and Cambridge, MA (U.S.), September 1 5 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its second
View HTML
Toggle Summary ERYTECH to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
ERYTECH to Present at the H.C. Wainwright 23 rd Annual Global Investment Conference Cambridge, MA (U.S.) and Lyon (France), September 6 , 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2021
                 Monthly information related to total number of voting rights and shares composing the share capital – August 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -
View HTML
Top